Abstract
AbstractAddressing the pressing demand for rapid and inexpensive coagulation testing in cardiovascular care, this study introduces a novel application of repurposed COVID-19 rapid antigen tests (RATs) as paper-based lateral flow assays (LFAs) combined with machine learning for coagulation status evaluation. By further developing a mobile app prototype, we present a platform that enables clinicians to perform immediate and accurate anticoagulant dosing adjustments using existing post-pandemic resources. Our proof-of-concept employs a random forest machine learning classifier to interpret image feature variations on RAT NC membrane, correlating red blood cell (RBC) wicked diffusion distance in recalcified citrated whole blood with changes in coagulative viscosity, easily interpreted. Enhanced by confocal imaging studies of paper microfluidics, our approach provides insights into the mechanisms dissecting coagulation components, achieving high classification precision, recall, and F1-scores. The inverse relationship between RBC wicked diffusion distance and enoxaparin concentration paves the way for machine learning to inform real-time dose prescription adjustments, aligning with individual patient profiles to optimize therapeutic outcomes. This study not only demonstrates the potential of leveraging surplus RATs for coagulation management but also exemplifies a cost-effective, rapid, and smart strategy to enhance clinical decision-making in the post-pandemic era.
Graphical Abstract
Funder
National Health and Medical Research Council
MRFF Cardiovascular Health Mission Grant
Snow Medical
National Heart Foundation of Australia
Nano Institute, University of Sydney
Office of Global and Research Engagment
NSW Cardiovascular Capacity Building Program
MRFF Early to Mid-Career Researchers Grant
New South Wales Government
National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care Yorkshire and Humber
McCusker Charitable Foundation
National Heart Foundation of Australia Vanguard Grant
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Guy S, Kitchen S, Maclean R, Van Veen JJ. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban. Int J Lab Hematol. 2015;37(6):834–43. https://doi.org/10.1111/ijlh.12414.
2. Avidan MS, Despotis GJ. Is the activated clotting time dangerous? Anesthesiology. 2005;103(4):904–904. https://doi.org/10.1097/00000542-200510000-00040.
3. Chlebowski MM, Baltagi S, Carlson M, Levy JH, Spinella PC. Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO. Crit Care. 2020;24(1):19. https://doi.org/10.1186/s13054-020-2726-9.
4. Cardiovascular diseases (CVDs). 21. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)#:~:text=Cardiovascular%20diseases%20%28CVDs%29%20are%20the%20leading%20cause%20of,85%25%20were%20due%20to%20heart%20attack%20and%20stroke.
5. Amini M, Zayeri F, Salehi M. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017. BMC Public Health. 2021;21(1):401. https://doi.org/10.1186/s12889-021-10429-0.